Fundraising Fox
Lixte Biotechnology Holdings
East Setauket, US · Founded 2006 · Delaware corporation · 4 employees on LinkedIn
Find your way into Lixte Biotechnology Holdings
Sign up to see every warm intro you have to Lixte Biotechnology Holdings
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lixte Biotechnology Holdings team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Lixte develops cancer therapies, focusing on precision oncology and clinical drug development. The company works on advancing innovative treatments in the oncology field.
Founders & leadership
Lixte Biotechnology Holdings was founded in 2006 by John Kovach.
JK
John KovachFounder & CEOHe previously directed comprehensive cancer centers at Mayo Clinic and City of Hope National Medical Center, with expertise in medical oncology, anti-cancer drug pharmacology, and clinical drug development.
BV
Bas van der BaanCSOBas van der Baan is Chief Scientific Officer at Lixte Biotechnology Holdings, a precision oncology company developing cancer therapies. He brings 25+ years of biotechnology industry experience, including prior roles as CEO of a NASDAQ-listed company and co-founder of a molecular diagnostics company, along with a Master's degree in Molecular Sciences.
GP
Geordan PursgloveCEO
PS
Peter StazzoneCFO
W(
Winson (Sze Chun) HoNamed on SEC filing
PP
Philip PalmedoNamed on SEC filing
Board
SF
Stephen FormanBoard director
YY
Yun YenBoard director
Reported raises · per SEC filings
Form D private placements$8M disclosed across 2 rounds · 2018–2023
▶$3.5MraisedAug 2023 · 1 investors · BiotechnologyRule 506(b)
▶$3.5MraisedAug 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bas van der BaanDirector
- Yun YenDirector
- James MiserExecutive Officer
- Robert WeingartenExecutive Officer
- Regina BrownDirector
- John KovachExecutive Officer, Director
- Rene BernardsDirector
- Eric FormanExecutive Officer
- Stephen FormanDirector
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- Minimum investment
- $3.5M
- Sales commissions
- $210K
- Placement agents
- A.G.P. / ALLIANCE GLOBAL PARTNERS
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.5MraisedDec 2018 · 15 investors · BiotechnologyRule 506(b)
▶$4.5MraisedDec 2018 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen FormanDirector
- Yun YenDirector
- Winson (Sze Chun) HoDirector
- John KovachExecutive Officer, Director
- Philip PalmedoDirector
- Offering amount
- $4.5M
- Amount sold
- $4.5M
- Minimum investment
- $50K
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
Kite PharmaKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Dialectic TherapeuticsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Companies working in the same space as Lixte Biotechnology Holdings.
Frequently asked questions
- What does Lixte Biotechnology Holdings do?
- Lixte develops cancer therapies, focusing on precision oncology and clinical drug development. The company works on advancing innovative treatments in the oncology field.
- Who founded Lixte Biotechnology Holdings?
- Lixte Biotechnology Holdings was founded by John Kovach in 2006.
- How much funding has Lixte Biotechnology Holdings raised?
- Lixte Biotechnology Holdings has disclosed $8M raised across 2 rounds.
- Where is Lixte Biotechnology Holdings headquartered?
- Lixte Biotechnology Holdings is headquartered in East Setauket, US.